At Ghana's Centre for Plant Medicine Research in Mampong, patients seeking relief from anxiety are handed bottles of herbal sedatives prepared on site. The government-run clinic sees more than 16,000 people a month, yet no published trial has compared its remedies against diazepam, the cheap benzodiazepine that dominates care elsewhere. The disagreement over which should come first is not abstract. It shapes what patients are given, what they are told, and what happens when the sedation wears off.

Ghana's Quiet Anxiety Treatment Gap

Ghana has few psychiatric beds and fewer psychiatrists per capita than the regional average. For most people with anxiety, the practical choice is not between two clinics but between a herbal preparation and a tablet bought over the counter. Diazepam is widely available in pharmacies and licensed chemical shops, often dispensed without a prescription review or a follow-up appointment.

The Mampong centre, set up by the government in 1976, fills part of that gap. Its outpatient clinic treats more than 16,000 patients a month, according to the centre's own figures, and many arrive with complaints that map onto anxiety: palpitations, sleeplessness, a persistent sense of dread. Families choose it because the cost is lower and the stigma is softer than a psychiatric hospital.

That choice is not irrational. A related piece on this site about Kenya's mental health fund shows how reimbursement rules can push community clinics out of the formal system, leaving patients to pay out of pocket. Ghana's herbal clinic operates largely outside insurance, but its prices are within reach for many households.

The geography matters as much as the price. Ghana's psychiatrists cluster in Accra and Kumasi, and a patient in a district town may face a day of travel and a night's lodging before seeing one. The Mampong clinic draws from a wide catchment precisely because it sits closer to where people live. A consultation there is a bus ride; a psychiatric referral is a journey that costs wages as well as fares.

What the Mampong Centre Actually Offers

The centre produces its own herbal medicines and runs an outpatient clinic that treats more than 16,000 patients a month, according to its published description. Preparations are made on site from locally sourced plants, and patients are seen by practitioners trained in both herbal medicine and basic clinical assessment. The clinic does not publish outcome data on anxiety, and its staff have not released trial results comparing their sedatives with conventional drugs.

That absence is the crux. Without published data, clinicians cannot know whether the preparations relieve anxiety as reliably as diazepam, whether they interact with other medicines, or whether long-term use carries dependence risk. The centre's defenders say the clinic's volume is itself a form of evidence: thousands of returning patients suggest the remedies work well enough for them.

Sceptics counter that volume measures demand, not efficacy. A patient who feels calmer after a bitter draught may be responding to the ritual, the attention, or the alcohol content of a tincture. None of those is the same as a measured reduction in anxiety scores, and none tells a clinician what to do when a patient stops.

There is a middle position that rarely gets aired. The clinic could function as a triage point rather than a terminus. A practitioner who screens for severe anxiety, suicidal thinking, or a physical cause such as an overactive thyroid could refer those patients onward and treat the rest. That model needs a screening tool the staff trust and a referral pathway that actually accepts patients. Neither is documented at Mampong, and the clinic's published material does not describe one.

Diazepam's Evidence and Its Costs

Diazepam has decades of trial evidence behind it for acute anxiety. It works quickly, costs little, and is stocked in almost every pharmacy in Ghana. For a patient in crisis, that combination is hard to beat. The drug's problems are equally well documented: dependence can develop after a few weeks of regular use, and withdrawal without tapering can be severe, sometimes dangerous.

Those risks are manageable when prescribing is monitored. In Ghana, monitoring is the weak link. A patient who buys diazepam from a chemical shop may never see a prescriber again, and may not know that stopping abruptly can trigger rebound anxiety, insomnia, and in rare cases seizures. The drug's cheapness and availability make it the default, not because it is always the best choice but because the alternatives are harder to organise.

Guidance from the World Health Organization has long cautioned that benzodiazepines are indicated for short courses in acute anxiety and are not a treatment for the underlying condition. That advice assumes a prescriber who reviews the patient, tapers the dose, and offers something else alongside. Where those conditions are missing, the drug's safety profile is a laboratory finding rather than a clinical reality.

This site has argued in a related piece on depression screening that a positive score is only useful if the treatment it refers to exists. The same logic applies here. A diagnosis of anxiety is not a plan, and a prescription without a review is not monitoring.

The Trial That Has Not Been Run

No head-to-head trial of a Mampong herbal sedative against diazepam has been published in Ghana. That single missing study sits underneath most of the disagreement. Without it, psychiatrists who favour herbal care cannot point to comparative efficacy, and those who oppose it cannot point to comparative harm. Both sides are arguing from plausibility.

Herbal preparations also vary batch to batch, which complicates trial design. The active compounds in a plant extract depend on the season, the soil, and the extraction method. A trial that fixes one batch may not reflect what a patient receives six months later. Regulators lack a clear pathway for licensing herbal anxiolytics, so the clinic operates in a space between traditional medicine and formal pharmaceuticals.

A trial would also need a comparator that reflects actual practice. Running a herbal preparation against a supervised diazepam taper is a different question from running it against diazepam alone, and the second comparison flatters the drug by removing the monitoring that makes it safe. Designing the study well costs more than designing it quickly, which is one reason funders have stayed away.

A related piece on occupational asthma screening makes a similar point about missing data: when a condition is common but unmeasured, the absence of evidence becomes the status quo. Ghana's anxiety care has settled into that status quo, with two parallel systems and no bridge between them.

Where the Disagreement Actually Lies

Some clinicians at Mampong and elsewhere see herbal care as a reasonable first-line option for mild to moderate anxiety, particularly where cost and stigma keep patients away from psychiatric services. They argue that a preparation with a long history of use and few reported serious adverse events deserves a place in the formulary, even without a randomised trial.

Others warn that unmonitored sedation is its own risk. A herbal sedative that dulls anxiety can also dull alertness, and a patient who drives or operates machinery may be in danger without knowing it. The lack of standardised dosing means one bottle may be stronger than the next, and no one is recording falls, confusion, or interactions with alcohol.

Both sides agree on one thing: the safety data are missing. Where they split is on what to do while waiting for it. One camp would expand the clinic's role and record outcomes; the other would restrict herbal anxiolytics until a trial reports. Patient preference often decides the question before either camp gets a say.

The Money Behind the Stalemate

Research funding follows priorities, and anxiety in West Africa has rarely topped them. Donor attention in global mental health has leaned toward severe conditions such as psychosis and epilepsy, and toward task-sharing programmes that train lay workers. A comparative trial of a herbal sedative does not fit neatly into either bucket, and no obvious funder has claimed it.

The centre's own budget is another constraint. A government research institute that also runs a busy clinic has to choose between serving patients today and answering questions for tomorrow. Clinic revenue pays salaries; trials pay nothing until they finish. That incentive shapes what gets published, and it is not unique to Ghana.

Regulation adds a further layer. Herbal medicines in Ghana are registered through a dedicated authority that assesses safety and quality, but registration is not the same as proof of efficacy for a specific indication. A product can be lawfully sold and still lack the evidence a psychiatrist would want before recommending it as first-line care. The gap between lawful and proven is where most of this argument lives.

Practical Steps for Patients and Clinicians

Ask what is in the preparation and how much of each plant is in a dose. A clinic that cannot answer that question is asking for trust it has not earned.

Do not stop diazepam abruptly if you have been taking it regularly for more than a few weeks. Request a taper plan from a prescriber, and follow it even if you feel fine.

Report sedation, falls, or confusion to whichever practitioner supplied the remedy, whether herbal or conventional. Those events are the raw material of the safety data that do not yet exist.

Push for recorded outcomes at herbal clinics. Ask whether the clinic tracks anxiety scores before and after treatment, and whether it publishes them. A clinic that measures its results can defend them.

This article is informational and does not constitute personalised medical advice. Patients should consult a qualified clinician about their own care.